#### Check for updates

#### **OPEN ACCESS**

EDITED BY Erdem Tüzün, Istanbul University, Türkiye

REVIEWED BY Nagehan Ersoy Tunali, Istanbul Medeniyet University, Türkiye Sinem Bireller, Acıbadem University, Türkiye Zhenyu Gong, Technical University of Munich, Germany

\*CORRESPONDENCE Amirmohammad Alborzi 🖂 amir224.alborzi2020@gmail.com

<sup>†</sup>These authors have contributed equally to this work

RECEIVED 17 December 2023 ACCEPTED 12 February 2024 PUBLISHED 29 February 2024

#### CITATION

Hasani F, Masrour M, Jazi K, Ahmadi P, Hosseini Ss, Lu VM and Alborzi A (2024) MicroRNA as a potential diagnostic and prognostic biomarker in brain gliomas: a systematic review and meta-analysis. *Front. Neurol.* 15:1357321. doi: 10.3389/fneur.2024.1357321

#### COPYRIGHT

© 2024 Hasani, Masrour, Jazi, Ahmadi, Hosseini, Lu and Alborzi. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# MicroRNA as a potential diagnostic and prognostic biomarker in brain gliomas: a systematic review and meta-analysis

## Fatemeh Hasani<sup>1,2†</sup>, Mahdi Masrour<sup>3†</sup>, Kimia Jazi<sup>4,5</sup>, Payam Ahmadi<sup>6</sup>, Saba sadat Hosseini<sup>1,2</sup>, Victor M. Lu<sup>7</sup> and Amirmohammad Alborzi<sup>1</sup>\*

<sup>1</sup>Neuroscience Research Center, Golestan University of Medical Sciences, Gorgan, Iran, <sup>2</sup>Gastroenterology and Hepatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran, <sup>3</sup>School of Medicine, Tehran University of Medical Sciences, Tehran, Iran, <sup>4</sup>Clinical Research and Development Center, Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran, <sup>5</sup>Student Research Committee, Faculty of Medical Sciences, Medical University of Qom, Qom, Iran, <sup>6</sup>Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran, <sup>7</sup>Department of Neurosurgery, University of Miami, Miami, FL, United States

**Introduction:** Brain neoplasms and central nervous system (CNS) disorders, particularly gliomas, have shown a notable increase in incidence over the last three decades, posing significant diagnostic and therapeutic challenges. MicroRNAs (miRNAs) have emerged as promising biomarkers due to their regulatory role in gene expression, offering potential enhancements in glioma diagnosis and prognosis.

**Methods:** This systematic review and meta-analysis, adhering to PRISMA guidelines, included 25 studies for diagnostic accuracy and 99 for prognostic analysis, published until August 27th, 2023. Studies were identified through comprehensive searches of PubMed, Web of Science, and Scopus databases. Inclusion criteria encompassed peer-reviewed original research providing sensitivity, specificity, and area under the curve (AUC) for miRNAs in glioma diagnosis, as well as survival outcomes with hazard ratios (HRs) or mean survival.

**Results and discussion:** Meta-analysis demonstrated miRNAs' high diagnostic accuracy, with a pooled sensitivity of 0.821 (95% CI: 0.781–0.855) and specificity of 0.831 (95% CI: 0.792–0.865), yielding an AUC of 0.893. Subgroup analysis by specimen type revealed consistent accuracy across blood, cerebrospinal fluid (CSF), and tissue samples. Our results also showed miRNAs can be potential prognostic biomarkers. miRNAs showed significant associations with overall survival (OS) (pooled HR: 2.0221; 95% CI: 1.8497–2.2105), progression-free survival (PFS) (pooled HR: 2.4248; 95% CI: 1.8888–3.1128), and disease-free survival (DFS) (pooled HR: 1.8973; 95% CI: 1.1637–3.0933) in tissue specimens. These findings underscore miRNAs' potential as valuable biomarkers for improving glioma diagnosis and prognosis, offering insights for enhancing clinical decision-making and patient outcomes.

#### KEYWORDS

glioma, MicroRNAs, brain neoplasms, prognosis, diagnosis

# **1** Introduction

Over the last three decades, there has been a notable rise in the incidence of brain neoplasms and central nervous system (CNS) disorders. Gliomas, constituting more than 50% of all brain and CNS tumors (1), are primary brain tumors originating from neuroglial stem or progenitor cells (2, 3). They represent 24.8% of all brain and other CNS tumors and are

responsible for 82.4% of malignant brain tumors (4). In 2023, the American Cancer Society predicted that there will be approximately 24,810 new cases of cancer and 18,990 deaths related to CNS tumors, which are the primary causes of cancer-related deaths among individuals under the age of 20 (5). According to the 2020 Global Cancer Observatory (GLOBOCAN) report, there are an estimated 308,102 new cases of CNS and 251,329 deaths attributed to this type of cancer (6). Additionally, a 2019 statistical report by CBTRUS revealed that the average annual age-adjusted incidence rate (AAAIR) of gliomas in the United States was approximately 7.87 per 100,000 people between 2012 and 2016 (7). Despite the continued use of surgery, radiotherapy, and chemotherapy with alkylating agents as standard treatments, the diagnosis and treatment of brain tumors, especially gliomas, present significant challenges for future neurologists, neurosurgeons, and oncologists. Consequently, the imperative is to discover novel molecular targets for enhancing both glioma diagnosis and prognosis, with the potential utilization of microRNAs (miRNAs) as biomarkers.

miRNAs are small noncoding RNA molecules that control gene expression (8) and act as oncogenes or tumor suppressors in different types of cancers (9, 10). Several studies indicate that miRNAs regulate genes by binding to their 3'-untranslated regions (3'-UTR), influencing processes such as differentiation, apoptosis, proliferation, and development (11-13). Moreover, MiRNA binding sites exhibit a broader distribution, extending beyond the 3' UTR to encompass diverse mRNA regions such as coding sequence, the 5' UTR, and even within promoter regions (14). Binding of miRNAs to the 5' UTR and coding regions leads to gene expression silencing, underscoring their regulatory influence on gene function (15, 16). MiRNA interactions with promoter regions have been observed to activate transcription, highlighting their diverse role in regulating gene expression across different stages (17). A growing body of evidence shows that miRNAs are abnormally expressed in several diseases, notably tumors (18, 19). Numerous studies have reported the use of miRNAs as biomarkers for diagnosing and predicting the prognosis of human gliomas (20–22).

miRNA-21 has been extensively researched and is often highly expressed in various cancers, potentially acting as a diagnostic and prognostic biomarker. High expression of miRNA-21 was notably associated with poorer survival in glioma patients (23, 24). miRNA-21 also exhibits consistent and high diagnostic accuracy in detecting glioma (25). High miR-15b expression was also associated with a significantly poorer overall survival rate in glioma patients, emerging as an independent prognostic factor (26). In another investigation miR-15b expression closely correlated with a shortened overall survival, indicating that miR-15b may serve as an intrinsic factor exerting a crucial role in the malignant progression of gliomas (27). Moreover, upregulation of miR-193b was detected in the serum, tissues, and cells of glioma patients compared to controls, with a high diagnostic accuracy for glioma. miR-193b levels were also correlated with a poorer survival (28). Also, miR-210 has been identified as a promising non-invasive biomarker for both the diagnosis and prognosis of glioma (29). However, conflicting results have emerged owing to differences in specimen type, sample size, or study design. Furthermore, glioma cells exhibit increased levels of miR-10b, miR-130a, miR-221, miR-125, and miR-9 compared with normal brain tissue. Elevated expression of miR-10b and miR-210 in gliomas has been linked to unfavorable outcomes (30, 31).

While many studies have suggested the diagnostic and prognostic potential of miRNAs in gliomas, the findings have been

inconsistent and inconclusive. Therefore, the aim of this study was to assess the accuracy of miRNAs in diagnosing and predicting the prognosis of brain gliomas through a systematic review of the literature and meta-analysis of quantitative metadata.

### 2 Methods

Our study was designed in accordance with the methodology outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline (32). We registered our systematic review and meta-analysis protocol with the registration number CRD42023459785 in PROSPERO.

# 2.1 Information sources and search strategy

We carried out a thorough search for academic papers in PubMed, Web of Science (ISI), and Scopus from their inception until August 27st, 2023. We used a search query to systematically search titles and abstracts within our selected databases. The search queries are shown in Supplementary Table S1.

### 2.2 Inclusion criteria

We included all peer-reviewed original research studies that provided sensitivity, specificity, and area under the curve (AUC) measurements of miRNAs as diagnostic markers for gliomas. To assess prognostic accuracy, we conducted peer reviews of original research studies that presented survival curves for overall survival (OS), diseasefree survival (DFS), progression-free survival (PFS), and recurrencefree survival (RFS), with or without hazard ratio (HR), risk ratio (RR), or mean survival, and their corresponding 95% confidence intervals (CIs) associated with miRNAs as prognostic markers for gliomas.

Both prospective and retrospective human studies were included. Eligible studies involved cancer patients and healthy participants. For diagnostic accuracy, studies should compare miRNAs against established reference controls to assess sensitivity and specificity, regardless of assay duration. We opted not to set eligibility criteria based on healthcare settings and the total number of participants in the included studies.

Studies that had not undergone peer review, were not in the English language, utilized datasets, or fell into categories such as letters, comments, reviews, case reports, and case series were considered ineligible and were therefore excluded from our analysis.

Following the elimination of duplicate entries, two authors (FH and AA) evaluated the titles and abstracts of all identified studies according to inclusion and exclusion criteria. Upon gathering studies that met the eligibility criteria, both authors separately conducted a thorough examination of the complete texts. Any disagreements or discrepancies were resolved by consensus.

### 2.3 Data extraction

Two reviewers (FH, SS) independently collected the following data for diagnosis using a standardized extraction method: author's name, publication year, cancer type, specimen type, sample size, name of the miRNA, control group characteristics, alterations in miRNA levels in patients compared to the control group, sensitivity, specificity, area AUC along with its 95% CI, *p*-value, Positive Predictive Value (PPV), and Negative Predictive Value (NPV). To ensure accuracy, a third researcher (AA) examined the potential disparities between the data extraction files, and any differences were addressed through mutual agreements.

For prognosis, two independent reviewers (FH and PA) obtained the following data: author's name, publication year, cancer type, specimen type, sample size, miRNA name, control group characteristics, alterations in miRNA levels, OS, DFS, PFS, RFS, HR, RR, or mean survival, *p*-value, and their corresponding 95% CIs. A third researcher (AA) examined the potential disparities between the data extraction files.

### 2.4 Quality assessment

The Newcastle-Ottawa Scale (NOS) was used to assess the quality of the included (33). This tool was designed and recommended by the Cochrane Handbook to appraise the quality of observational studies (34). In the case of cohort studies, the primary domains to be assessed consist of selection, comparability, and outcome, with potential maximum ratings of four, two, and three stars, respectively. According to this scale, a rating of  $\geq$ 7 indicates a high quality. Two authors (FH and KJ) independently appraised the quality of the studies, and in the event of any discrepancies, a third author, PA, intervened to resolve the matter. The quality assessment of the included studies can be found in Supplementary Tables S3, S4.

### 2.5 Data analysis

The bivariate random effects model, which was created by Reitsma et al., was used to combine the results of studies that discussed diagnostic specificity and sensitivity. Additionally, this model calculates the summary receiver operating characteristic (sROC) curve and AUC, both of which serve as measures of diagnostic accuracy (35). For studies that only provided AUC as the reported outcome, meta-analysis was conducted using a random-effects model with the inverse variance method. The random-effects model was employed to account for the anticipated heterogeneity across the included studies.

The prognostic significance of miRNAs was reported in OS, PFS, DFS, RFS, and EFS. Meta-analysis of prognostic values was conducted using the inverse variance method with logarithmic HRs as the primary measure. HRs were divided into two categories: HRs with values less than one and HRs with values more than one. This was done because an HR of less than one implies that the examined miRNA is cancer-protective, while an HR of more than one indicates that the miRNA is cancer-promoting. This classification was performed without considering the regulatory mechanisms linked to the miRNA under investigation.

The studies were further divided into subgroups based on the specimen sample (tissue, blood, or cerebrospinal fluid [CSF]) used in the evaluation of miRNA expression as well as the combination of the specimen sample and the quality assessment outcome. A quality score of nine or higher was deemed "good quality" in studies; seven or higher was deemed "fair quality," and less than seven was deemed "poor quality."

The statistical analyses and visualizations were performed in R version 4.2.2 (R Core Team [2021], Vienna, Austria) using the "meta" and "mada" packages (36, 37). The standard errors of the AUCs and HRs for the meta-analysis were calculated using 95% CI. If the AUC CI was not available, the AUC value and sample size (the Hanley and McNeil method) were used to estimate the standard error (38, 39). We employed  $I^2$  and tau<sup>2</sup> statistics to assess heterogeneity. Statistical significance was determined by an  $I^2$  value exceeding 50% and a *p*-value <0.05.

# **3** Results

### 3.1 Basic characteristics

Following an initial examination of the database, a total of 4,102 titles were obtained. After the removal of duplicate articles, 3,330 articles were evaluated for inclusion. 307 full-text reviewed. 25 studies met the inclusion criteria for diagnostic accuracy, while 99 studies met the inclusion criteria for prognosis. Of the 99 articles, 58 were included in the meta-analysis. Figure 1 depicts the PRISMA flowchart, which illustrates the process of selecting and excluding the studies.

Table 1 provides a concise summary of the primary characteristics of the included studies in case of diagnosis. The basic characteristics of the included studies on prognosis are provided in Supplementary Table S2. Papers in the diagnosis segment were published between 2012 and 2022, whereas those in the prognosis section were published between 2010 and 2023. The diagnostic segment included 2,268 glioma cases and 1,334 healthy controls. To assess OS, the prognosis section analyzed 14,786 glioma cases. In addition, the PFS of 3,751 cases was evaluated. Moreover, the RFS of 443 patients from China was analyzed. We also evaluated the DFS of 460 Chinese patients.

# 3.2 Meta-analysis of diagnostic accuracy of microRNAs in glioma

The model demonstrated miRNA to have a pooled sensitivity of 0.821 (95% CI: 0.781-0.855, p<0.001) and a pooled specificity of 0.831 (95% CI: 0.792-0.865, p<0.0001) in diagnostic evaluations involving 3,111 glioma cases and 2,045 controls (Figure 2). This analysis included 33 diagnostic evaluations using blood specimens and 2 diagnostic evaluations using CSF. The estimated I<sup>2</sup> value using the Zhou and Dendukuri approaches was found to be 10.6%. The p-value for the test examining the equality of sensitivities across studies was found to be less than  $2 \times 10^{-16}$ . Similarly, the *p*-value for the test assessing the equality of specificities was also less than 2e<sup>-16</sup>. Upon generation of the summary ROC curve (Supplementary Figure S1), the calculated AUC for all studies was determined to be 0.893. The diagnostic evaluation of glioma using microRNAs in blood specimens, consisting of 33 evaluations, yielded a cumulative sensitivity of 0.823 (95% CI: 0.782-0.857, p<0.001) and a pooled specificity of 0.833 (0.792–0.866, *p* < 0.001) involving 3,069 glioma cases and 2,016 controls. The estimated  $I^2$  value using the Zhou and Dendukuri approach was found to be 12.9%. The test conducted to assess the equality of sensitivities among the blood studies yielded a *p*-value of less than  $2 \times 10^{-16}$ . Similarly, the test conducted to evaluate



the equality of specificities also resulted in a *p*-value of less than  $2 \times 10^{-16}$ . The AUC for the blood specimen studies was 0.895. Since there have only been two studies reporting on the sensitivity and specificity of microRNAs in CSF, a meta-analysis in this specific subgroup was not conducted.

The AUC values of microRNAs for detection of glioma were reported in all 42 included studies. Using the random effect model, the pooled AUC for all studies involving 3,532 glioma cases and 2,209 controls was 0.8791 (95% CI: 0.8631–0.8952, p < 0.0001,  $l^2 = 94.3\%$ ) (Figure 3). The studies were divided into 4 subgroups: blood, CSF, tissue, and blood and tissue, depending on the kind of specimen used to evaluate microRNA expression. The AUC for the blood specimen subgroup with 35 evaluations involving 3,338 glioma cases and 2,089 controls was 0.8776 (95% CI: 0.8608–0.8945;  $l^2 = 95.1\%$ ). The pooled AUC for the CSF specimen subgroup with 3 evaluations involving 52 cases and 37 controls was 0.8658 (95% CI: 0.7310–1.0007;  $l^2 = 76.4\%$ ). The pooled AUC for the tissue specimen subgroup with 3 evaluations involving 30 cases and 15 controls was 0.8845 (95% CI: 0.8042–0.9649;

 $I^2$  = 0.0%). Only one study with 112 cases and 68 controls used both blood and tissue samples simultaneously, with an AUC of 0.9030 (95% CI: 0.8596–0.9464). The test for differences between subgroups was not statistically significant (*p* = 0.7533).

Based on the findings of the quality assessment, diagnostic studies were further categorized, with quality scores of 9 and above indicating "Good quality," 7 and above indicating "Fair quality," and less than 7 indicating "Poor quality." "Good quality – Blood" subgroup resulted in an AUC of 0.9051 (95% CI: 0.8825–0.9277;  $I^2$ =95.3%) (Supplementary Figure S2).

# 3.3 Meta-analysis of the prognostic accuracy of microRNAs in glioma

11,518 cases of glioma were included in 75 prognostic analyses that provided OS HRs higher than one. The overall HR for these studies was 2.0221 (95% CI: 1.8497–2.2105, p<0.0001;  $l^2$ =74.1%,

ID	Author, year	Country	Type of Study	Glioma type	Case samples	Control samples	Case N.	Control N.	miRNA	Down/Up Regulation	Sensitivity (%)	Specificity (%)	AUC
1	Baraniskin, 2012 (40)	Germany	Cohort	Glioma	CSF	CSF	10	10	miR-15b	upregulation	90	100	0.96
2	Wang, 2012	China	Cohort	GBM	Plasma	Plasma	50	10	miR-21	upregulation	90	100	0.93
	(41)								miR-128	upregulation	90	100	1
									miR-342-3p	upregulation	90	100	1
3	Lai, 2015 (42)	China	Cohort	Glioma	Serum	Serum	136	50	miR-210	upregulation	91.27	72.5	0.927
4	Sun, 2015 (43)	China	Cohort	Glioma	Serum	Serum	151	53	miR-128	downregulation	86.75	88.68	0.9095
5	Chai, 2015 (44)	China	Case control	Glioma	Serum	Serum	166	75	miR-199a-3p	downregulation	_	_	0.8466
6	Xiao, 2016 (45)	China	Case control	Glioma	Serum	Serum	112	54	miR-182	upregulation	58.5	85.2	0.778
7	Yue, 2016 (46)	China	Cohort	Glioma	Serum	Serum	64	45	mir-205	downregulation	86.3	92.2	0.935
8	Zhao,2016 (47)	China	Case control	Glioma	Serum	Serum	118	84	mir-451a	downregulation	81.4	79.7	0.816
9	Huang, 2017	China	Case	Glioma	Serum	Serum 100	100	50	mir-376a	_	81	82	0.872
	(22)		control						miR-376b	-	82	78	0.89
									miR-376c	-	90	70	0.837
10	Tang, 2017 (21)	China	Case control	Glioma	Serum	Serum	74	74	miR-122	_	91.9	81.1	0.939
11	Xu, 2017 (48)	China	Case	Glioma	Serum	Serum	47	45	miR-17	upregulation	89.3	55.3	0.78
			control						miR-130a	upregulation	70.2	65.2	0.72
									miR-10b	upregulation	44.6	93.6	0.72
12	Lan, 2018 (49)	China	Cohort	Glioma	Serum	Serum	60	43	miR-301a	upregulation	86.2	93.2	0.937
13	Santangelo,	Italy	Case	GBM	Serum	Serum	100	30	miR-21	upregulation	84	77	0.84
	2018 (50)		control						miR-222	upregulation	57	100	0.8
									miR-124-3p	-	89	63	0.78
14	Kopkova, 2019 (51)	Czech Republic	Cohort	GBM	CSF	CSF	32	19	miR-124-3p, mir-10a, let-7b	-	73	75	0.789
15	Ohno, 2019 (52)	Japan	Cohort	Glioma	Serum	Serum	157	200	miR-4763-3p, miR-1915-3p, miR-3679-5p	upregulation	99	97	0.99

10.3389/fneur.2024.1357321

Hasani et al.

TABLE 1 (Continued)	
---------------------	--

ID	Author, year	Country	Type of Study	Glioma type	Case samples	Control samples	Case N.	Control N.	miRNA	Down/Up Regulation	Sensitivity (%)	Specificity (%)	AUC
16	Wang, 2019 (53)	China	Case control	Glioma	Serum	Serum	100	100	miR-214	upregulation	90	71	0.885
17	Zhang, 2019 (54)	China	Case control	GBM	Serum	Serum	117	50	miR-145-5p	upregulation	84.6	78	0.895
18	Zhu, 2019 (28)	China	Case control	Glioma	Serum, tissues and cells	Serum, tissues and cells	112	68	miR-193b	upregulation	79.5	86.8	0.903
19	Chen, 2020 (55)	China	Case control	Glioma	Serum	Serum	122	60	miR-720	upregulation	71.3	83.3	0.773
20	Lan, 2020 (29)	China	Case control	Glioma	Serum	Serum	91	50	mir-210	upregulation	83.2	94.3	0.856
21	Sun, 2021 (56)	USA	Case control	Glioma	Serum	Serum	124	36	miR-2276-5p	downregulation	_	_	0.8107
22	Catelan, 2022 (57)	Italy	Case control	Glioma	Serum	Serum	91	30	miR-222	_	_	_	0.756
23	Geng, 2022 (58)	China	Case control	GBM	CSF	CSF	10	8	miR-9	upregulation	_	_	0.8
24	Nikolova, 2022	Bulgaria	Case	Glioma	Brain tissue	Brain tissue	10	5	mir-21	upregulation	-	_	0.908
	(59)		control						mir-10b	upregulation	_	_	0.867
									mir-7	downregulation	_	_	0.861
25	Wu, 2022 (60)	Russia	Cohort	Glioma	Serum	Serum	77	85	miR-155	downregulation	66.7	76.9	0.68
									miR-410	upregulation	65.7	74.1	0.67
									miR-181a	upregulation	73.34	86	0.83
									miR-181b	upregulation	68.21	82.75	0.78
							114	85	miR-155	downregulation	82.3	84.1	0.92
									miR-410	upregulation	86.8	94.21	0.97
									miR-181a	upregulation	87.5	96.7	0.97
									miR-181b	upregulation	93.1	88.7	0.94



p < 0.0001). In the tissue specimen subgroup, which included 68 evaluations, the pooled HR was 1.9836 (95% CI: 1.8106–2.1731;  $I^2 = 73.9\%$ ). With seven evaluations, the blood specimen subgroup's HR was 2.4547 (95% CI: 1.7178–3.5078;  $I^2 = 62.0\%$ ). The test for differences across subgroups was not statistically significant (p = 0.2570) (Figure 4). 25 prognostic evaluations involving 3,602 glioma cases provided OS HRs less than one, yielding a pooled HR of 0.6154 (95% CI: 0.5366–0.7058, <0.0001;  $I^2 = 66.7\%$ , p < 0.0001). For the tissue specimen subgroup (with 24 evaluations), the pooled HR was 0.6120 (95% CI: 0.5301–0.7066;  $I^2 = 67.5\%$ ). The blood specimen subgroup had only one evaluation with an HR of 0.6190 (95% CI: 0.3827–1.011). The test for subgroup differences was not statistically significant (p = 0.9645) (Figure 5).

Based on the findings of the quality assessment, diagnostic studies were further categorized, with quality scores of 9 and above indicating "Good quality," 7 and above indicating "Fair quality," and less than 7 indicating "Poor quality." Quality + specimen subgrouping resulted in non-significant subgroup differences in studies with OS HRs greater than one (p=0.0838). The "Good quality – Tissue" subgroup had the highest pooled HR, 3.1931 (95% CI: 1.6832–6.0574;  $l^2$ =59.2%). The "Good quality – Blood" subgroup had HR 2.2632 (95% CI: 0.6735– 7.6047;  $l^2$ =86.6%) (Supplementary Figure S3). For studies with OS HRs less than one, quality + specimen subgrouping similarly yielded a non-significant test for subgroup differences (p=0.6546). The combined HR for the "Fair quality – Tissue" subgroup was 0.6561 (95% confidence interval: 0.5407–0.7961;  $l^2$ =72.5%) (Supplementary Figure S3).

Author, year (IncRNA)	AUC	SE	Case N.	Control N.			AUC		AUC	95%-CI	Weigh
Specimen = Blood											
Wu, 2022 (miR-410)	0.67	0.04	77	85					0.67	[0.59; 0.75]	2.0%
Wu, 2022 (miR-155)	0.68	0.04	77	85			- 1		0.68	[0.60; 0.76]	2.0%
Xu, 2017 (miR-10b)	0.72	0.05	47	45			-		0.72	[0.63: 0.81]	1.8%
Xu. 2017 (miR-130a)	0.72	0.05	47	45			-		0.72	[0.63: 0.81]	1.7%
Catelan, 2022 (miR-222)	0.76	0.04	91	30		-	1		0.76	[0.68: 0.84]	2.0%
Chen. 2020 (miB-720)	0.77	0.03	122	60			_		0.77	[0.71: 0.84]	2.3%
Xiao, 2016 (miR-182)	0.78	0.05	112	54		_	-		0.78	[0 68: 0 88]	1.6%
Santangelo, 2018 (miR-124-3p)	0.78	0.05	100	30		-	-		0.78	[0 67: 0 89]	1 4%
(u 2017 (miB-17)	0.78	0.04	47	45					0.78	[0.70: 0.86]	1 9%
Nu 2022 (miR-181b)	0.78	0.03	77	85					0.78	[0 71: 0 85]	2 3%
Santangelo, 2018 (miR-222)	0.80	0.05	100	30					0.80	[0.70: 0.90]	1.6%
Sun 2021 (miR-2226)	0.81	0.00	124	36			121		0.81	[0.70, 0.30]	2.3%
7 has 2016 (mir 451a)	0.01	0.04	110	94					0.01	[0.74, 0.00]	2.5 /
(hab,2010 (hill-451a)	0.02	0.03	77	04					0.82	[0.70, 0.07]	2.0%
vu, 2022 (MIR-1818)	0.83	0.03	100	65			and a second sec		0.83	[0.77; 0.89]	2.5%
luang, 2017 (miR-376c)	0.84	0.03	100	50					0.84	[0.77; 0.90]	2.4%
Santangelo, 2018 (miR-21)	0.84	0.05	100	30			-		0.84	[0.75; 0.93]	1.7%
chai, 2015 (miR-199a-3p)	0.85	0.04	166	75					0.85	[0.77; 0.92]	2.1%
an, 2020 (mir-210)	0.86	0.03	91	50			-	_	0.86	[0.80; 0.92]	2.5%
luang, 2017 (mir-376a)	0.87	0.03	100	50					0.87	[0.82; 0.93]	2.7%
Vang, 2019 (miR-214)	0.89	0.02	100	100			-		0.89	[0.84; 0.93]	2.9%
luang, 2017 (miR-376b)	0.89	0.03	100	50			-	-	0.89	[0.84; 0.94]	2.8%
zhang, 2019 (miR-145-5p)	0.90	0.02	117	50			-	•	0.90	[0.85; 0.94]	2.9%
Sun, 2015 (miR-128)	0.91	0.02	151	53			+		0.91	[0.87; 0.95]	3.19
Vu, 2022 (miR-155)	0.92	0.02	114	85			+		0.92	[0.88; 0.96]	3.2%
ai, 2015 (miR-210)	0.93	0.02	136	50				-	0.93	[0.89; 0.96]	3.2%
Vang, 2012 (miR-21)	0.93	0.07	50	10					0.93	[0.80; 1.06]	1.19
(ue, 2016 (mir-205)	0.94	0.02	64	45					0.94	[0.89: 0.98]	2.9%
an. 2018 (miR-301a)	0.94	0.03	60	43			+	-	0.94	[0.87: 1.00]	2.49
Tang 2017 (miR-122)	0.94	0.02	74	74					0.94	[0 90: 0 98]	3 19
$N_{\rm H} = 2022 ({\rm miR}_{-}181{\rm b})$	0.94	0.02	114	85			-		0.94	[0.00, 0.00]	3.49
Nu, 2022 (miR-181a)	0.04	0.01	114	85					0.07	[0.05; 0.00]	3 70
Nu. 2022 (miR-101a)	0.07	0.01	114	95					0.97	[0.95; 0.99]	3.70
Nu, 2022 (IIII(-+10)	0.97	0.01	157	200					0.97	[0.95, 0.99]	2.00
Mana, 2013 (miR-4703-5p, miR-1815-5p, miR-3078-5p	1.00	0.00	50	200					1.00	[0.99, 0.99]	3.97
(vang, 2012 (miR-120)	1.00	0.00	50	10					1.00	[1.00, 1.00]	3.97
wang, 2012 (miR-342-3p)	1.00	0.00	50	10			1		1.00	[1.00, 1.00]	3.97
Heterogeneity: $l^2 = 95\%$ , $\tau^2 = 0.0017$ , $\rho < .01$									0.88	[0.00; 0.09]	69.37
specimen = CSF											
opkova, 2019 (miR-124-3p, mir-10a, let-7b)	0.79	0.06	32	19		-	1		0.79	[0.67; 0.91]	1.2%
Geng, 2022 (miR-9)	0.80	0.10	10	8		( <del></del>	æ		0.80	[0.61; 0.99]	0.6%
Baraniskin, 2012 (MiR-15b)	0.96	0.02	10	10					0.96	[0.92; 1.00]	3.0%
Random effects model leterogeneity: $l^2 = 76\%$ , $\tau^2 = 0.0104$ , $p = .01$									0.87	[0.73; 1.00]	4.7%
pecimen = Tissue											
likolova, 2022 (mir-7)	0.86	80.0	10	5					0.86	[0.70; 1.02]	0.8%
likolova, 2022 (mir-10b)	0.87	0.08	10	5					0.87	[0.72; 1.02]	0.9%
likolova, 2022 (mir-21)	0.91	0.06	10	5					0.91	[0.79; 1.03]	1.39
Random effects model							-		0.88	[0.80; 0.96]	2.9%
leterogeneity: $l^2 = 0\%$ , $\tau^2 = 0$ , $p = .87$											
pecimen = Blood and Tissue	0.00	0.02	110	68					0.00	10 86. 0 051	2.00
nom 2019 (min-1930)	0.90	0.02	112	00					0.90	[0.00, 0.95]	3.0%
Random effects model							•		0.88	[0.86; 0.90]	100.0%
leterogeneity: $l^2 = 94\%$ , $\tau^2 = 0.0017$ , $p < .01$					1		1	1	1		
Test for overall effect: $z = 107.18$ ( $p = 0$ )					0.4	0.6	0.8	1	1.2		

3,639 cases of glioma were included in 19 prognostic analyses that provided PFS HRs higher than one. These evaluations were all conducted on tissue specimens. The overall HR for these studies was 2.4248 (95% CI: 1.8888–3.1128, p < 0.0001;  $I^2 = 83.2\%$ , p < 0.0001) (Figure 6). 10 prognostic evaluations provided PFS HR less than one, yielding a pooled HR of 0.2881 (95% CI: 0.1433–0.5791, p = 0.0005;  $I^2 = 85.2\%$ , p < 0.0001). These evaluations were all conducted on tissue specimens (Figure 6). Study quality subgrouping resulted in significant subgroup differences in studies with OS HRs greater than one (p = 0.0141). The "Fair quality" subgroup had the highest pooled HR, 4.0372 (95% CI: 2.4861–6.5561;  $I^2 = 61.4\%$ ) (Supplementary Figure S4). All the studies with OS HRs less than one were in the "Poor quality" subgroup with pooled HR 0.2881 (95% CI: 0.1433-0.5791;  $I^2 = 85.2\%$ ) (Supplementary Figure S4).

182 cases of glioma were included in 2 prognostic analyses that provided DFS HRs higher than one. One evaluation was on tissue specimens and one was on blood specimens. The overall HR for these studies was 1.8973 (95% CI: 1.1637–3.0933, p=0.0102;  $I^2$ =52.2%, p=0.1480) (Supplementary Figure S5). 3 prognostic evaluations provided DFS HR less than one, yielding a pooled HR of 0.7816 (95% CI: 0.6479–0.9428, p=0.0100;  $I^2$ =80.9%, p=0.0054). Two evaluations were on blood specimens and one on tissue specimens (Supplementary Figure S5).

Cussimon - Ti-				1.0				
Specimen = Tissue	0.02	0.25	150	:	1.02	10 62: 1 601	1 40/	
Znao, 2013 (miR-182)	0.03	0.25	107		1.03	[0.63; 1.69]	1.4%	
Supak, 2019 (miR-223)	0.10	0.05	244	E :	1.11	[1.00; 1.22]	2.3%	
Stupple 2010 (miR-21-5p)	0.13	0.08	107		1.14	[0.97, 1.33]	2.2%	
Stupak, 2019 (miR-31)	0.20	0.05	107		1.22	[1.02, 1.47]	2.1%	
Ou 2021 (miR-21)	0.21	0.07	107		1.23	[1.07, 1.41]	2.270	
Qu, 2021 (miR-196a-5p)	0.24	0.07	12		1.27	[1.10, 1.47]	2.2%	
Costo 2011 (miR-20a)	0.29	0.13	203	100	1.33	[1.02; 1.71]	1.9%	
Costa, 2011 (miR-596)	0.30	0.14	34	and a	1.35	[1.01; 1.78]	1.9%	
Vice 2010 (miR-196a)	0.33	0.14	253	The second se	1.39	[1.06; 1.81]	1.9%	
Alao, 2019 (mik-150-5p)	0.43	0.17	591	100	1.55	[1.10; 2.14]	1.0%	
Harmanaan 2012 (miR-K12-0-3p)	0.43	0.23	102		1.54	[0.90, 2.43]	1.470	
Delfino 2011 (miR-26)	0.44	0.22	253	and a second sec	1.54	[1.00, 2.30]	1.9%	
Delfino 2011 (miR-23b)	0.45	0.10	253	and a second sec	1.57	[1.10, 2.10]	1.6%	
Hua 2017 (miR-620)	0.40	0.15	106	and a second sec	1.62	[1.10, 2.33]	1.0%	
Kai 2021 (miR-030)	0.40	0.34	72	and a	1.62	[0.03, 3.41]	1.5%	
Dolfino 2011 (miR-524-50)	0.40	0.21	253	NUMBER OF	1.62	[1.07, 2.44]	1 7%	
Delfino, 2011 (miR-101)	0.49	0.10	253	1000	1.05	[1.15, 2.52]	2 10/	
Yuo 2017 (miP 221)	0.50	0.10	165	100	1.65	[1.33, 2.02]	1.6%	
Delfino 2011 (miR-148a)	0.50	0.20	252		1.00	[1.14, 2.49]	2 10/	
Hua 2017 (miR-140d)	0.51	0.10	106		1.00	[1.05, 2.02]	1 1 1 0/	
Hua 2017 (miR-208-3p)	0.52	0.33	106		1.09	[1.00, 3.79]	1.1%	
Hua 2017 (miR-17-5p)	0.53	0.34	106		1.70	[1.03, 4.01]	1 10/	
LV 1 2018 (miP 220c)	0.54	0.31	71		1.74	[1.07, 3.03]	1 20/	
Barbano 2014 (miD 156)	0.55	0.20	32		1.74	[1.00, 2.90]	1 70/	
Delfino 2011 (miD EEE)	0.50	0.10	252	and a second	1.00	[1.20, 2.03]	2 0.04	
Yue 2015 (miP-140)	0.59	0.12	162		1.00	[1.41, 2.30]	1 20%	
Delfino 2011 (miP.bbrf1 1)	0.00	0.29	252		1.02	[1.05, 5.23]	1 /0/	
Xiao 2019 (miR-10h 5n)	0.00	0.23	501		1.03	[1.10, 2.00]	1 4 %	
Ly L 2017 (miP-320b)	0.62	0.24	65		1.00	[1 14: 3 46]	1 2%	
Zhao 2013 (miP 106a)	0.02	0.20	156		1.00	[1.14, 3.40]	1 20/	
Li 2021 (miD 874)	0.60	0.20	105		1.91	[1.11, 3.20]	1.270	
$X_{1,2} = 2016 (miR-574)$	0.09	0.30	87	-	2 11	[1.10, 5.01]	0.9%	
Delfino 2011 (miR-300)	0.75	0.38	253		2.11	[1.23, 5.39]	1 5%	
Gao 2013 (miR-34a)	0.75	0.22	151		2.11	[1.37, 3.20]	1.0%	
Oin 7 2017 (miR-34a)	0.76	0.20	69		2.13	[1.24, 3.07]	1.2 /0	
Mana 2010 (miR-5200)	0.76	0.29	108		2.13	[1.20, 3.00]	1 1 1 1/	
Delfino 2011 (miR-445-50)	0.76	0.30	253		2.14	[1.10, 3.00]	1 7%	
Wang 2021 (miR-1246)	0.70	0.10	00	600	2.14	[1.31, 3.03]	1 / 9/	
Zhao 2013 (miR-196a)	0.75	0.24	156	- the second sec	2.20	[1.33, 3.30]	1.4%	
chen 12017 (miR-203)	0.81	0.35	100		2.20	[1.02, 0.04]	1.0%	
Wang 2019 (miR-124)	0.83	0.30	60		2.20	[1.25: 4.07]	1 1%	
Delfino 2011 (miR-124)	0.00	0.30	253	1000	2.29	[1.20, 4.07]	1 7%	
Wei 2022 (miR-575)	0.92	0.10	107		2.52	[1.76, 5.30]	0.9%	
Chen 2019 (miR-3653)	0.99	0.34	168	1.00	2.55	[1.20, 0.00]	1.0%	
Delfino 2011 (miR-324-5n)	1.00	0.21	253		273	[1 80: 4 14]	1.5%	
Sippl 2019 (miR-26a)	1.01	0.36	80		2.75	[1.35: 5.59]	0.9%	
Delfino, 2011 (miR-k12-1)	1.02	0.23	253		2.77	[1.78: 4.31]	1.5%	
Cheng, 2017 (miR-144-3p)	1.03	0.38	111		2.79	[1.13: 5.02]	0.9%	
Zhu, 2019 (miR-193b)	1.06	0.32	122		2.88	[0.90: 3.17]	1.1%	
Xiao, Q. 2017 (miR-130b)	1.07	0.26	129		2.91	[1.74: 4.88]	1.3%	
Bai, Q 2017 (miR-1301)	1.08	0.31	184		2.93	[1.65: 5.63]	1.1%	
Zhou, Y. 2018 (miR-599)	1.08	0.33	184		2.93	[1.63: 5.87]	1.1%	
Delfino, 2011 (miR-565)	1.09	0.28	253		2.97	[1.71: 5.16]	1.2%	
Feng, Q, 2019 (miR-770)	1.10	0.33	145		3.02	[1.22; 4.44]	1.0%	
Xue, 2018 (miR-133b)	1.16	0.38	97		3.20	[1.83; 8.05]	0.9%	
Qin, 2017 (miR-142)	1.17	0.44	97		3.22	[1.24; 6.96]	0.7%	
Cheng, 2015 (miR-218)	1.17	0.26	98		3.23	[1.50; 4.17]	1.3%	
Wang, 2018 (miR-1231)	1.21	0.34	154		3.36	[1.17; 4.47]	1.0%	
Wu, 2019 (miR-526b-3p)	1.21	0.33	158		3.37	[1.48; 5.33]	1.1%	
Xiao, 2021 (miR-310a)	1.22	0.51	100		3.38	[1.38; 10.02]	0.6%	
Song, 2019 (miR-662)	1.26	0.29	108		3.52	[2.15; 6.78]	1.2%	
Zhang, 2017 (miR-211)	1.28	0.29	82		3.61	[2.15; 6.75]	1.2%	
Ye, n, 2017 (miR-204)	1.47	0.48	75	÷ *	4.34	[1.81; 11.70]	0.7%	
Lan, 2018 (miR-301a)	1.48	0.29	60	:	4.40	[3.10; 9.60]	1.2%	
Liu, 2014 (miR-132)	1.50	0.44	113	:	- 4.47	[2.91; 16.22]	0.7%	
Zhong, 2015 (miR-134)	1.58	0.42	162	÷	4.87	[1.93; 9.88]	0.8%	
Ye, 2016 (miR-183)	1.99	0.46	105		7.34	[2.11; 12.70]	0.7%	
Random effects model				•	1.98	[1.81; 2.17]	91.9%	
Heterogeneity: $I^2 = 74\%$ , $\tau^2 = 0$ .	0839, p < 0	0.01						
Specimen = Blood			100			Contra testara	Sc 1930	
Xiao, 2016 (miR-182)	0.22	0.27	112		1.25	[0.89; 2.53]	1.3%	
Chen, 2020 (miR-720)	0.39	0.25	122		1.48	[1.12; 2.97]	1.4%	
Zhang, 2016 (miR-221)	0.88	0.27	50		2.40	[1.42; 4.05]	1.3%	
Zhang, 2016 (miR-222)	1.03	0.26	50		2.81	[1.70; 4.65]	1.3%	
Chai, 2016 (miR-199a-3p)	1.27	0.41	55		3.55	[1.24; 6.19]	0.8%	
Lai, 2015 (miR-210)	1.35	0.31	136	; <del></del>	3.84	[2.09; 7.08]	1.1%	
Lan, 2020 (miR-210)	1.46	0.37	91	÷ ==	4.31	[1.94; 8.13]	0.9%	
Random effects model				-	2.45	[1.72; 3.51]	8.1%	
Heterogeneity: $I^2 = 62\%$ , $\tau^2 = 0$ .	1419, p = (	0.01		1		•		
Random effects model				•	2.02	[1.85; 2.21]	100.0%	

FIGURE 4

The overall survival hazard ratios meta-analysis for HRs greater than one.

Author, year (IncRNA)	logHR	SE(logHR)	Case N.	Hazard Ratio	HR	95%-CI	Weigh
Specimen = Tissue				11			
Delfino, 2011 (miR-bhrf1-1)	-2.41	1.00	253		0.09	[0.01; 0.51]	0.5%
Delfino, 2011 (miR-189)	-2.12	0.95	253		0.12	[0.02; 0.83]	0.5%
Yuan, G, Q, 2017 (miR-139-5p, miR-17-5p and miR-9-3	p) -1.28	0.39	48		0.28	[0.13; 0.60]	2.4%
Delfino, 2011 (miR-512-3p)	-1.27	0.43	253		0.28	[0.12; 0.65]	2.1%
Zheng, H., 2021 (miR-939-5p)	-0.89	0.33	105		0.41	[0.22; 0.78]	3.2%
Costa,F, 2011 (miR-367)	-0.84	0.28	34		0.43	[0.25; 0.76]	3.8%
Zhao, 2013 (miR-106a)	-0.81	0.29	156		0.45	[0.26; 0.80]	3.7%
Wu, Z, 2012 (miR-328)	-0.78	0.29	100		0.46	[0.26; 0.82]	3.6%
Dong, Q, 2019 (miR-374a)	-0.75	0.67	48		0.47	[0.13; 1.73]	1.0%
Barbano, 2014 (miR-1296)	-0.73	0.31	32		0.48	[0.26; 0.89]	3.3%
Zhao, 2013 (miR-106a)	-0.69	0.27	156		0.50	[0.30; 0.85]	4.0%
Barbano, 2014 (miR-383)	-0.58	0.27	32		0.56	[0.33; 0.96]	4.0%
Hua, Z, 2017 (miR-145-5p)	-0.53	0.28	106		0.59	[0.29; 0.88]	3.8%
Hua, Z, 2017 (miR-182)	-0.51	0.29	106		0.60	[0.29; 0.92]	3.6%
Xue, L, 2017 (miR-221)	-0.50	0.20	165		0.60	[0.40; 0.88]	5.5%
Delfino, 2011 (miR-34c)	-0.48	0.19	253		0.62	[0.43; 0.90]	5.8%
Delfino, 2011 (miR-140)	-0.43	0.29	253		0.65	[0.37; 1.15]	3.7%
Li, H, 2017 (miR-320a)	-0.35	0.07	120	+	0.71	[0.62: 0.81]	9.1%
Hua, Z, 2017 (miR-15b-5p)	-0.27	0.34	106		0.76	[0.40; 1.52]	3.0%
Delfino, 2011 (miR-572)	-0.27	0.78	253		0.76	[0.06: 1.20]	0.7%
Stupak, E. V., 2019 (miR-221)	-0.21	0.13	107	<b>H</b>	0.81	[0.58: 0.97]	7.5%
Wang, J. F., 2019 (miR-214)	-0.12	0.03	130		0.89	10.83: 0.931	9.9%
Delfino, 2011 (miR-137)	-0.06	0.17	253	(王)	0.94	[0.67: 1.32]	6.2%
Zhao, 2013 (miR-182)	-0.03	0.24	156	-	0.97	[0.61: 1.55]	4.6%
Random effects model				*	0.61	[0.53: 0.71]	95.5%
Heterogeneity: $I^2 = 67\%$ , $\tau^2 = 0.0532$ , $p < 0.01$				1			
Specimen = Blood							
Sun, J., 2021 (miR-2276-5p)	-0.48	0.25	124		0.62	[0.35; 0.93]	4.5%
Random effects model				· · · ·	0.62	[0.54; 0.71]	100.0%
Heterogeneity: $l^2 = 67\%$ , $\tau^2 = 0.0486$ , $p < 0.01$ Fest for subgroup differences: $\chi_1^2 = 0.00$ , df = 1 ( $p = 0.96$ )				0.1 0.51 2 10			
RE 5							

# 3.4 Prognostic and diagnostic significance of individual microRNAs

Some microRNAs have been subjected to multiple evaluations regarding their prognostic or diagnostic accuracy. These microRNAs were analyzed individually. Table 2 and Figure 7 summarizes all of the findings.

### 3.5 Publication bias

Figure 8 illustrates the funnel plot portraying the standard error for the studies included in the meta-analysis. An asymmetrical funnel plot suggests potential publication bias. To investigate this, statistical tests such as Begg's rank correlation test and Egger's linear regression test were employed. The results indicate significant evidence of publication bias among the included studies (Begg's test *p*-values = 0.0908 and Eggers' test *p*-values < 0.0001).

# 4 Discussion

### 4.1 Diagnostic value

In this study, 3,111 glioma patients and 2,045 healthy controls in 25 articles indicated a cumulative sensitivity of 0.821 (95% CI: 0.781–0.855, p < 0.001) and a pooled specificity of 0.831 (95% CI:

0.792-0.865, p < 0.0001) in diagnostic evaluations. The pooled AUC for all studies containing 3,532 glioma cases and 2,209 controls was 0.8791 (95% CI: 0.8631–0.8952, *p* < 0.0001, *I*<sup>2</sup> = 94.3%). In line with our findings, Qu and colleagues indicated sensitivity, specificity, and AUC of 0.87, 0.87, and 0.93 evaluating the role of miRNAs on diagnosis of glioma, however, authors only investigated RNA profiling for the sources of heterogeneity and all different sample types from CSF, serum, and blood were investigated together (61). In this study, assessing the diagnostic accuracy, through subgroup and meta-regression analysis we divided the studies into four subgroups involving blood, CSF, tissue, and blood and tissue. The pooled AUC for each group was found 0.8776, 0.8658, 0.8845, and 0.9030, respectively. However, the difference between subgroups was not significant (p = 0.7533). Moreover, the diagnostic evaluation of glioma using microRNAs in blood samples, showed a cumulative sensitivity and a pooled specificity of 0.823 (95% CI: 0.782-0.857, p<0.001) and 0.833 (0.792-0.866, p<0.001), respectively, suggesting a remarkable diagnostic efficacy for gliomas. Similarly, He et al. explored the diagnostic value of miRNA via meta-analysis reporting overall pooled sensitivity, specificity, and AUC 0.84, 0.84, and 0.9, respectively for serum samples, considering only Asian and Chinese patients as a strong possible limitation (62). In our study, regarding limitations, this was almost resolved considering reports from Italy, Germany, China, Russia, Bulgaria, USA, Japan, and Czech Republique, thus, our findings could be more suitable for diagnostic performance compared to previous meta-analysis all around the world.

Author, year (IncRNA)	logHR	SE(logHR)	Case N	Hazard Ratio	HR	95%-CI	Weight
Specimen = Tissue				1 1			
Yang, M. 2017 (miR-21-5p)	0.05	0.09	244	· · · · · · · · · · · · · · · · · · ·	1.05	[0.88: 1.26]	7.0%
Delfino 2011 (miR-ul70-3p)	0.12	0.24	253	:	1.13	[0,71: 1,79]	5.8%
Delfino, 2011 (miR-222)	0.24	0.11	253		1.27	[1 02: 1.58]	6.8%
Delfino 2011 (miR-486)	0.43	0.16	253		1.53	[1.02, 1.00]	6.5%
Delfino 2011 (miR-222)	0.50	0.13	253	1000 C	1.65	[1.12, 2.00]	6.7%
Gao H 2013 (miR-34a)	0.69	0.10	151	and a second	2.00	[1 18. 3 30]	5 5%
Wang H 2021 (miR-1246)	0.00	0.24	90		2.00	[1.10, 0.00]	5.7%
Delfino $2011 (miR_{1240})$	0.83	0.24	253		2.20	[1.55; 3.40]	6 1%
Delfino, 2011 (miR-100)	0.03	0.20	253	and the second s	2.50	[1.55, 5.40]	5 2%
$V_{e} = 7 \text{ n} 2017 \text{ (miR-33)}$	1.00	0.30	75		2.05	[1.31, 4.03]	3.5%
Sippl C 2010 (miR 264)	1 12	0.40	20		2.00	[1.01, 0.70]	1 20/
$7_{\rm hu} \times \sqrt{2018} (miR-200)$	1.13	0.33	184	-	3.03	[1.44, 0.00]	5.0%
Dolfing 2011 (miR $k12.6.5n$ )	1.14	0.32	253	1	3.14	[1.93, 0.77]	5.6%
Delfino 2011 (miR-k12-0-5p)	1.10	0.20	253	1	3 10	[1.03, 5.20]	5.6%
$M_{\rm H}$ M 2010 (miR-K12-1)	1.10	0.20	158	and the second se	3.19	[1.93, 5.29]	1 3%
Zhong 2015 (miR-5205-50)	1.50	0.39	160	1 100	4.07	[1.27, 5.09]	4.3 /0
Dolfing, 2013 (IIIR-134)	1.40	0.30	252	1 100	4.27	[1.92, 0.02]	4.4%
Liu 2014 (miR-302)	1.70	0.47	200		6.20	[2.17, 13.00]	5.0%
Liu, 2014 (miR-132)	1.04	0.20	105		7.29	[4.91, 14.07]	3.3%
Fe, 2016 (miR-163)	1.99	0.56	105		1.20	[1.10, 9.73]	3.0%
Random effects model	0040	0.04			2.42	[1.69; 3.11]	100.0%
Heterogeneity: $T = 83\%$ , $\tau = 0.3$	2248, p <	< 0.01					
Random effects model					2 4 2	11 89. 3 111	100.0%
Heterogeneity: $l^2 = 83\%$ $\tau^2 = 0$	2248 n -	0.01			2.42	[1.00, 0.11]	100.070
Test for subgroup differences: $\chi$	$r_0^2 = 0.00,$	df = 0 (p = N)	A)	0.1 0.5 1 2 10			
Author, year (IncRNA)	logHR	SE(logHR)	Case N.	Hazard Ratio	HR	95%-CI	Weight
Specimen = Tissue							
Delfino 2011 (miR-512-3n)	-Inf	Inf	253		0.00	[0 00· 0 04]	0.0%
Delfino 2011 (miR-bart7)	-3 00	0.69	253		0.05	[0.01: 0.15]	8.9%
Delfino 2011 (miR-512-3n)	-2.66	0.67	253		0.07	[0.02: 0.28]	9.0%
Delfino, 2011 (miR-758)	2.53	0.50	253		0.08	[0.03: 0.21]	10.6%
Delfino, 2011 (miR-756)	1 51	0.30	253		0.00	[0.05; 0.21]	8.6%
Delfino, 2011 (miR-304)	1 20	0.75	253	and an a state of the state of	0.22	[0.05, 0.67]	12 10/
Dellino, 2011 (miR-143)	0.04	0.31	255	1	0.30	[0.10, 0.54]	12.1/0
Dellino, 2011 (miR-ui/0-3p)	-0.04	0.23	253		0.43	[0.27, 0.07]	12.7%
Dellino, 2011 (miR-466)	-0.30	0.27	253		0.74	[0.44; 1.25]	12.4%
Delfino, 2011 (miR-181c)	-0.20	0.24	253	1 100	0.82	[0.53; 1.35]	12.6%
Delfino, 2011 (miR-143)	-0.19	0.16	253		0.83	[0.61; 1.12]	13.0%
Random effects model				-	0.29	[0.14; 0.58]	100.0%
Heterogeneity: $I^2 = 85\%$ , $\tau^2 = 0$ .	.9495, p	< 0.01					
Random effects model				-	0.29	[0.14; 0.58]	100.0%
Heterogeneity: $I^2 = 85\%$ , $\tau^2 = 0$	.9495, p	< 0.01					
Test for subgroup differences: y	$c_0^2 = 0.00$	df = 0 (p = N)	IA)	0.1 0.51 2 10			
FIGURE 6							

A study conducted by Lai et al. showed a reliable diagnostic efficacy of miRNA-210 with a sensitivity, specificity, and AUC of 0.9127, 0.725, 0.927 (95%CI: 0.889–0.964), respectively (42). Additionally, Sun et al. comparing glioma patients to healthy individuals, demonstrated that with an AUC of 0.9095 (95%CI: 0.8695–0.9496), miRNA-128, could promisingly distinguish glioma showing the sensitivity and specificity of 0.8675 and 0.8868, respectively (43). Qu et al. also suggested miRNA-21 with, respectively, a pooled sensitivity, specificity, and AUC of 0.82, 0.94, and 0.95 presenting a high overall diagnostic accuracy (61).

In line with previous reports, we also approved the key roles of these miRNAs in diagnosis of glioma. Our findings approved the outstanding diagnostic role of miRNA-21, miRNA-128, and miRNA-210. The first biomarker has shown antiapoptotic effects, induced tumor invasion by targeting matrix metalloproteinase, and more importantly it has been involved in chemo-and radiotherapy resistance (63). Interestingly, the majority of studies agreed on the correlation of miRNA-21, and tumor grade and aggression. Assessing fresh frozen brain tissue samples, miRNA-21, showed the lowest concentrations in grade I and II tumors, increasing by reaching higher grades peaking

### $\mathsf{TABLE~2} \ \mathsf{Results~of~the~meta-analysis~summarized~for~microRNAs~with~multiple~evaluations.}$

MicroRNA	AUC evaluations	Poole [95	ed AUC % CI]	OS evaluations	Pooleo [95	Pooled OS HR PFS [95% CI] evaluatio		Pooled PFS H [95% CI]	
miR-181	4	0.8875	[0.8187; 0.9564]						
miR-21	3	0.8799	[0.8166; 0.9432]	3	1.2053	[1.0902; 1.3326]			
miR-376	3	0.8701	[0.8381;						
miR-10	2	0.7802	[0.6385;						
miR-128	2	0.9570	[0.8684;						
miR-155	2	0.8027	1.0456] [0.5676;						
miR-210	2	0.8957	1.0379] [0.8266;	2	4.0310	[2.5333;			
			0.9648]			6.4140]			
miR-222	2	0.7734	[0.7107; 0.8361]	2	2.3374	[1.7554; 3.1123]	2	1.4377	[1.1128; 1.8574]
miR-410	2	0.8227	[0.5287; 1.1166]						
miR-182				4	0.9545	[0.7369;			
miP 196				4	1 4868	[1 1949.			
					1.4000	1.8658]			
miR-320				4	1.4134	[0.8181; 2.4420]			
miR-221				4	1.1595	[0.6315; 2.1292]			
miR-26				3	1.9873	[1.2268;			
miR-106				2	0.4769	[0.3236;			
				2	2.0726	0.7029]			
m1K-134				2	2.9736	[1.3279; 6.6588]			
miR-148				2	1.6550	[1.4352;			
						1.9084]			
m1R-15				2	0.7696	[0.3972;			
miR-324				2	2.1018	[1.2603;			
						3.5051]			
miR-34				2	1.1298	[0.3374;			
miR-565				2	2.1694	5.7831]			
						3.4871]			
miR-bhrf1-1				2	0.4753	[0.0252; 8.9523]			
miR-k12				2	2.0703	[1.1646;	2	3.1900	[2.2334;
miR-143						3.0802]	2	0.5170	4.5563]
miR-486							2	1.0983	1.3982] [0.5404;
									2.2319]
miR-512							2	0.0700	[0.0187; 0.2619]
miR-ul70							2	0.6964	[0.2702; 1.7950]

Overall	survival ha	zard ratios		Progression-free survival hazard ratios					
Author, year (IncRNA) logi	HR SE(logHR) Case N.	Hazard Ratio HR	95%-CI	Author, year (IncRNA) logHR SE(logHR) Case N. Hazard Ratio HR 95%-Cl					
miRNA = miR-182 Hua, Z, 2017 (miR-182) -0. Xiao, 2016 (miR-182) 0 Zhao, 2013 (miR-182) 0. Zhao, 2013 (miR-182) -0. Random effects model	.510.29106.220.27112.030.25156.030.24156	0.60 1.25 1.03 0.97 0.95	[0.29; 0.92] [0.89; 2.53] [0.63; 1.69] [0.61; 1.55] [0.74; 1.24]	miRNA = miR-143 Defino, 2011 (miR-143) -1.20 0.31 253 0.30 [0.16; 0.54] Defino, 2011 (miR-143) -0.19 0.16 253 0.83 [0.61; 1.12] Random effects model Heterogenety, <sup>12</sup> = 81%, <sup>42</sup> = 0.4576, p < 0.01					
Heterogeneity: I <sup>2</sup> = 17%, t <sup>2</sup> = 0.0018, miRNA = miR-196 Delfino, 2011 (miR-196a) 0. Zhao, 2013 (miR-196a) 0. Zhao, 2013 (miR-196a) 0. Qu, S., 2021 (miR-196a-5p) 0.	p = 0.31 .33 0.14 253 .65 0.28 156 .81 0.27 156 .24 0.07 12	1.39 1.91 2.25 1.27	[1.06; 1.81] [1.11; 3.28] [1.32; 3.84] [1.10; 1.47]	ImiRVA = min-222         0.24         0.11         253         ■         1.27         [1.02; 1.58]           Defino, 2011 (miR-222)         0.50         0.13         253         ■         1.65         [1.29; 2.12]           Random effects model         Heterogeneity: I <sup>2</sup> = 58%, x <sup>2</sup> = 0.0200, p = 0.12         1.44         [1.11; 1.86]					
Random effects model Heterogeneity: $J^2 = 48\%$ , $\tau^2 = 0.0256$ , miRNA = miR-320	<i>p</i> = 0.12	• 1.49	[1.18; 1.87]	Defino, 2011 (miR-486) 0.30 0.27 253 − 0.74 [0.44; 1.25] Defino, 2011 (miR-486) 0.43 0.16 253 − 1.55 [1.12; 2.08] Random effects model 1.10 [0.54; 2.23] Heterogenety <i>l</i> <sup>+</sup> = 82%, <i>e</i> <sup>2</sup> = 0.2150, <i>p</i> = 0.02					
$ \begin{array}{ll} \text{Li, H, 2017 (miR-320a)} & -0. \\ \text{Lv, Q, L, 2017 (miR-320b)} & 0. \\ \text{LV, Q, I, 2018 (miR-320c)} & 0. \\ \text{Qin, C, Z, 2017 (miR-320d)} & 0. \\ \text{Qin, C, Z, 2017 (miR-320d)} & 0. \\ \text{Random effects model} \\ \text{Heterogeneity: } l^2 = 91\%, r^2 = 0.2556. \\ \end{array} $	$\begin{array}{ccccccc} 35 & 0.07 & 120 \\ 62 & 0.28 & 65 \\ 55 & 0.26 & 71 \\ 76 & 0.29 & 68 \\ p < 0.01 \end{array}$	0.71 1.85 1.74 2.13 1.41	[0.62; 0.81] [1.14; 3.46] [1.08; 2.96] [1.20; 3.80] [0.82; 2.44]	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$					
miRNA = miR-221 Xue, L, 2017 (miR-221) -0, Xue, L, 2017 (miR-221) 0, Stupak, E. V., 2019 (miR-221) -0, Zhang, 2016 (miR-221) 0, Random effects model Hetorogeneby: / <sup>2</sup> = 834, <sup>2</sup> = 0.3435,	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.60 0.81 2.40 1.16	[0.40; 0.88] [1.14; 2.49] [0.58; 0.97] [1.42; 4.05] <b>[0.63; 2.13]</b>	miRNA = miR-412 Defino, 2011 (miR+t2-4) 1.16 0.26 253 3.19 [1.93; 5.29] Defino, 2011 (miR+t2-65p) 1.16 0.26 253 3.19 [1.93; 5.29] Radom effects model Heterogenety, f = 0, p = 1.00 miRNA = miR-4170					
	$\begin{array}{ccccc} .44 & 0.22 & 193 \\ .21 & 0.07 & 107 \\ .13 & 0.08 & 244 \\ p = 0.39 \end{array}$	→ 1.54 → 1.23 → 1.14 ◆ 1.21	[1.00; 2.38] [1.07; 1.41] [0.97; 1.33] [1.09; 1.33]	$\begin{array}{c} \text{Deffino, 2011 (mR-4/70-3p)} & -0.84 & 0.23 & 253 \\ \text{Deffino, 2011 (mR-4/70-3p)} & 0.12 & 0.24 & 253 \\ \text{Random effects model} \\ \text{Heterogeneity, } l^2 = 85, l^2 = 0.421, p < 0.01 \\ \text{Heterogeneity, } l^2 = 90\%, r^2 = 0.8402, p < 0.01 \\ \text{Test for subgroup differences: } r^2_5 = 45.57, \text{ of } = 5 (p < 0.01) \\ \end{array}$					
miRNA = miR-26 Sippl, C., 2019 (miR-26a) 1. Delfino, 2011 (miR-26a) 0. Delfino, 2011 (miR-26a) 0. Random effects model Heterogeneity: J <sup>2</sup> = 80%, t <sup>2</sup> = 0.1329,	01 0.36 80 .29 0.13 253 .92 0.18 253 p < 0.01	2.75 1.33 2.52 1.99	[1.35: 5.59] [1.02; 1.71] [1.78: 3.58] [1.23; 3.22]	AUC values					
miRNA = miR-106 Zhao, 2013 (miR-106a) -0. Zhao, 2013 (miR-106a) -0. Random effects model Heterogeneity: I <sup>2</sup> = 0%, r <sup>2</sup> = 0, p = 0.7	.81 0.29 156 .69 0.27 156	0.45 0.50 0.48	[0.26; 0.80] [0.30; 0.85] [ <b>0.32; 0.70</b> ]	Author, year (incRNA)         AUC SE Case N. Control N.         AUC         AUC 95%-CI           mIRNA = mIR-181         0.83 0.03         77         85					
$\label{eq:miRNA} \begin{array}{l} miRNA = miR-134 \\ \mbox{Delfino, 2011 (miR-134) } 0. \\ \mbox{Zhong, 2015 (miR-134) } 1. \\ \mbox{Random effects model} \\ \mbox{Heterogeneity. } I^2 = 68\%, r^2 = 0.2383, \end{array}$	75 0.22 253 58 0.42 162 p = 0.08	2.11 4.87 2.97	[1.37; 3.25] [1.93; 9.88] [1.33; 6.66]	Wu, 2022 (mR+181b)         0.78 0.03         77         85         -0.76 [0.71: 0.83]           Wu, 2022 (mR+181b)         0.94 0.02         114         85         -0.40 [0.91: 0.97]           Random effects model         -0.89 [0.82; 0.36]         -0.89 [0.82; 0.36]         -0.89 [0.82; 0.36]           Heteroperber, '1 = 051, v <sup>2</sup> = 0.0144, p. < 01					
$\label{eq:miRNA} \begin{array}{l} miRNA = miR-148 \\ \mbox{Delfino, 2011 (miR-148a) } 0. \\ \mbox{Delfino, 2011 (miR-148a) } 0. \\ \mbox{Random effects model} \\ \mbox{Heterogeneity: } I^2 = 0\%, \tau^2 = 0, p = 0.9 \end{array}$	.50 0.10 253 .51 0.10 253	- 1.65 - 1.66 ◆ 1.65	[1.35: 2.02] [1.35: 2.02] [1.44; 1.91]	Wang_2012 (miR-21)         0.39 0.07         50         10					
	.27 0.34 106 .43 2.52 591 8	0.76 0.77	[0.40; 1.52] [1.10; 21415.00] <b>[0.40; 1.49]</b>	Haung, 2017 (mic-746a) 0.87 0.03 100 50					
$\label{eq:miRNA} \begin{split} &miRNA = miR-210 & 1.\\ &Lan, F., 2020 (miR-210) & 1.\\ &Lai, 2015 (miR-210) & 1.\\ &Random effects model\\ &Heterogeneity. I^2 = 0\%, \tau^2 = 0, p = 0.8 \end{split}$	.46 0.37 91 .35 0.31 136	4.03	[1.94; 8.13] [2.09; 7.08] [2.53; 6.41]	miRIAA = miR-10 0.72 [0.63; 0.81] 0.72 [0.63; 0.81] 0.72 [0.63; 0.81] 0.72 [0.63; 0.81] 0.72 [0.63; 0.81] 0.72 [0.63; 0.81] 0.72 [0.63; 0.81] 0.72 [0.64; 0.72] 0.72 [0.64; 0.92] 0.73 [0.64; 0.92] 0.74 [0.64; 0.92]					
miRNA = miR-222           Delfino, 2011 (miR-222)         0.           Zhang, 2016 (miR-222)         1.           Random effects model         1.           Heterogeneity: $l^2 = 0\%, \tau^2 = 0, p = 0.3$ 1.	.76 0.18 253 .03 0.26 50	2.14 2.81 2.34	[1.51; 3.03] [1.70; 4.65] [1.76; 3.11]	Sun, 2015 (mR-128)         0.91 0.02         151         S3         ■         0.91 [0.87; 0.95]           Wang, 2012 (mR-128)         1.00 0.00         50         10         ■         1.00 [1.00; 1.00]           Random Hicks model         ●         ●         0.95 [0.87; 1.85]         ●         0.95 [0.87; 1.85]					
$\label{eq:miRNA} \begin{split} &miRNA = miR-324 \\ & \mbox{Kai, Q., 2021 (miR-324-5p)} & 0. \\ & \mbox{Deffno, 2011 (miR-324-5p)} & 1. \\ & \mbox{Random effects model} \\ & \mbox{Heterogeneity: } i^2 = 67\%, i^2 = 0.0913, \\ & \mbox{Heterogeneity: } i^2 = 0.75, i^2 = 0.0913, \\ & \mbox{Heterogeneity: } i^2 = 0.0913, i^2 = 0.0913, \\ & \mbox{Heterogeneity: } i^2 = 0.0913, i^2 = 0.0913, \\ & \mbox{Heterogeneity: } i^2 = 0.0913, i^2 = 0.0913, \\ & \mbox{Heterogeneity: } i^2 = 0.0913, i^2 = 0.0913$	.48 0.21 72 .00 0.21 253 p = 0.08	1.62 2.73 2.10	[1.07; 2.44] [1.80; 4.14] [ <b>1.26; 3.51</b> ]	mRUAA × mR-155 Wu, 2022 (mR-155) 0.68 0.04 77 85 Wu, 2022 (mR-155) 0.92 0.02 114 85 Random Hicks model Heterogeneity, l <sup>2</sup> + 80%, s <sup>2</sup> + 0.272L p < 01					
$\label{eq:miRNA} \begin{array}{l} miRNA = miR-34 \\ \mbox{Gao, H, 2013 (miR-34a)} & 0. \\ \mbox{Delfino, 2011 (miR-34c)} & -0. \\ \mbox{Random effects model} \\ \mbox{Heterogeneity: } l^2 = 93\%, \ t^2 = 0.7048, \ , \end{array}$	.76 0.28 151 .48 0.19 253 <i>p</i> < 0.01		[1.24; 3.67] [0.43; 0.90] [0.34; 3.78]	midDA * mix-210 0.86 0.03 91 50					
$\label{eq:miRNA} \begin{split} &miRNA = miR.565 & 0 \\ & \text{Delfino, 2011} (miR.565) & 0 \\ & \text{Delfino, 2011} (miR.565) & 1 \\ & \text{Random effects model} \\ & \text{Heterogeneity:} \ l^2 = 62\%, \ r^2 = 0.0779, \ . \end{split}$	.59 0.12 253 .09 0.28 253 ρ = 0.10	1.80 2.97 2.17	[1.41; 2.30] [1.71; 5.16] <b>[1.35; 3.49]</b>	Santangele 2018 (mR-222) 0.80 0.05 100 30 0.80 (07.0 0.01) Catalean, 202 (mR-222) 0.76 0.04 91 30 0.76 (0.68, 0.84) Random effects model					
$\label{eq:miRNA} \begin{split} & \text{miRNA} = \text{miR-bhrf1-1} \\ & \text{Delfino, 2011} (\text{miR-bhrf1-1}) & -2 \\ & \text{Delfino, 2011} (\text{miR-bhrf1-1}) & 0 \\ & \text{Random effects model} \\ & \text{Heterogeneity: } l^2 = 88\%, r^2 = 4.0069, \end{split}$	.41 1.00 253 .60 0.23 253	• 0.09 	[0.01; 0.51] [1.16; 2.88] [0.03; 8.95]	Wu, 2022 (mR-410)         0.67 0.04         77         85					
miRNA = miR-k12 Delfino, 2011 (miR-k12-1) 1. Delfino, 2011 (miR-k12-6-3p) 0. Random effects model	.02 0.23 253 .43 0.23 253	2.77 1.54 2.07	[1.78; 4.31] [0.98; 2.43] [ <b>1.16; 3.68</b> ]	NUC					
Heterogeneity: $l^2 = 70\%$ , $\tau^2 = 0.1200$ , Heterogeneity: $l^2 = 86\%$ , $\tau^2 = 0.2503$ , Test for subgroup differences: $\chi^2_{16} = 10$	p < 0.07 p < 0.01 01.31, df = 16 (p < 0.01) 0	0.2 0.5 1 2 5 7							
IGURE 7									

Results of the meta-analysis summarized for microRNAs with multiple evaluations.

in GBM samples (24, 64–67). miRNA-128, known as a tumor suppressor and an favorable diagnostic biomarker in glioma (67, 68).

A recent study by Lin et al. revealed that the expression was considerably inhibited in glioma tissues, resulting in tumor cell growth and invasion by elevating COX-2 mRNA and protein expression (69). Under hypoxic situation as a major feature of the glioma microenvironment, reduction in miR-210, reduces the inhibiting effects of this miRNA on Bcl-2 19 kD interacting protein (BNIP3) gene expression which results in lower oxidative stress, less mitochondrial damage, and eventually reduced cell death (70–72). We also found the remarkable diagnostic efficacy of miRNA-181a and b in addition to miRNA-376b. Previous studies has also approved that miRNA 181 family was downregulated in glioma compared to normal brain tissue (73, 74). A study demonstrated that all the subtypes of miRNA-181,



particularly type c, exhibited significant decrease with glioma progression (75). Although suppressing effects in melanoma, Huang et al. previously proved the early diagnostic role of miRNA-376 a, b, and c by their aberrant expression across tumor progression (22, 76).

There also has been further reports according to the role of miRNAs in glioma diagnosis. Serum miRNA-214 previously revealed an outstanding diagnostic value (AUC: 0.885, 95%CI: 0.833-0.926), increasing gradually with the grade of glioma increase (53). Serum exosomal miR-301a and miR-454-3p in discriminating glioma patients from healthy participants has also showed high sensitivity and specificity (49, 77). In a previous study, Zhi et al. found a panel with 9 miRNAs for diagnosis of astrocytoma with an outrageous sensitivity (0.933), specificity (0.945), and AUC (0.9722, 95%CI: 0.9501-0.9942) (78). Regarding mentioned panel, and the vast variety of miRNAs with high diagnostic values, we recommend that large sample and largescale studies to verify panels of miRNAs, could more extensively comply early diagnosis of this lethal malignancy. In addition, future studies should consider tumor grade, and the source of sample, simultaneously, in order to create standard panels, with suitable cut-off values for each stage and reach the goal of early diagnosis.

### 4.2 Prognostic value

Consistent to the present OS, PFS, and DFS analysis, a recent meta-analysis on prognostic value of miRNAs in glioma, affirmed that both overexpression of tumor promoting miRNAs and lower expression of suppressors, are significantly associated with poor prognosis in glioma (79). 11,518 cases of glioma, included in the resent study, showed OS HRs more than one (OS HR: 2.0221 (95% CI: 1.8497–2.2105, p < 0.0001;  $I^2 = 74.1\%$ )). In the subgroup analysis considering source of sample (tissue vs. blood), we found no difference among groups. 3,639 cases of glioma provided PFS HRs of 2.4248 (95% CI: 1.8888–3.1128, *p* < 0.0001; *I*<sup>2</sup> = 83.2%, p < 0.0001) on tissue specimens. 182 cases also showed DFS HRs of 1.8973 (95% CI: 1.1637–3.0933, p = 0.0102;  $I^2 = 52.2\%$ , p = 0.1480), on both tissue and blood samples. A systematic review and meta-analysis on 4,708 glioma patients, conducted by Zhang et al., revealed that the upregulation of miRNA-15b, 21, 148a, 196, 210, 221, as well as downregulation of miRNA-106a, and 124 are valuable prognostic biomarkers for poor outcomes (80). Our findings confirm the association of increased miRNA-210, and decreased miRNA-106 with poor prognosis of glioma. Noteworthy, not only advanced pathological grades, but also patients with high-grade glioma compared with low-grade, showed significantly augmented levels of miRNA-210, revealing the prognostic value of this biomarker (29, 42). However, this miRNA is known to be a biomarker for a vast variety of diseases such as cancers and cardiovascular disorders (81). This highlights the importance of assessing further miRNAs to more exclusively show the prognosis of glioma individually without being influenced by other underlying disease. Moreover, panels comprising both highly valued diagnostic and prognostic miRNAs could lead to sooner diagnosis, prognosis assessment, and therapeutic approach via a non-invasive method which could simply identify tumors not distinguished by imaging techniques.

There also have been individual studies. A meta-analysis on the cancer genome atlas glioma confirmed that overexpression of miRNA-21 is correlated with poorer OS (HR=1.27, 95% CI: 1.01, 1.59) and PFS (HR = 1.46, 95% CI: 1.17, 1.82) (23). Although poorer OS and PFS was approved for patients with III-IV grades, the results of multivariate Cox regression analysis of covariates, conversely, demonstrated that miRNA-21 was a potential prognostic biomarker for glioma independent of known associated factors such as age, and grade (23, 82). Our data also highlighted the correlation of miRNA-222 and poor prognosis, consistently, Song and colleagues, showed the association disregarding the tumor stage (HR of IV stage patients = 1.47; 95% CI, 1.11–1.94; *p*=0.01; HR of I–IV stage patients = 2.53; 95% CI, 1.76-3.63; p=0.82) (83). Higher levels of miRNA-193b (28), miRNA-155 (84), and miRNA-222 (83) were also strongly associated with poor glioma prognosis. However, although promising diagnostic value, miRNA-130b has shown no correlation with tumor invasion and progression, and OS/DFS in gliomas (85). There is no previously reported predictive panels. In addition, there is yet controversies whether prognostic value of miRNAs is influenced by the grade of glioma, which has to be furtherly assessed. Furthermore, future research should also evaluate miRNAs with high prognostic values after each treatment stages in order to clarify the association of miRNA levels and therapeutic response.

In this study we resolved previously reported limitations such as geographical, and sample source subgroup analysis. Moreover, for the first time we compared the validity of miRNAs for both diagnostic and prognostic approaches and suggested that further studies focus on glioma specified miRNAs to avoid effects of other diseases on miRNA levels. Additionally, it is necessary to develop a novel diagnostic and prognostic panel to sooner identify small tumors that are undetectable by imaging techniques, or address patients who are at high risk of imaging and surgery. We recommend that these panels could promisingly change the future early diagnosis, prognosis, and early treatment of glioma, ameliorating patients' morbidity and mortality rates. Although novel and positive aspects of our study, there are limitations worth to mention. First, number of available studies considering some miRNAs is limited, restricting definite conclusion. Second, some study population sizes were small. We require more high-quality studies with large populations to confirm our findings. Third, as mentioned, the prognostic and diagnostic value of miRNA biomarkers are significantly associated with tumor grade, a potential heterogenetity underlining the need of more detailed studies. Fourth, the miRNAs that has been discussed to date, are general tumor suppressors and promoters. There have been no reports of a glioma specific miRNA. Thus, further studies should focus on finding novel miRNAs or glioma specific panels exclusively, in order to differentiate glioma from other cancers, and improve the clinical application of miRNAs. Fifth, the prognostic reports were based on different indicators such as OS, DFS, and PFS, which could be the source of heterogeneity. Sixth, the included studies were all retrospective, deeming the lack of high-quality follow-up trials. Additionally, although different population were included from all around the world, still Chinese comply the majority. Last, but not least, there was a lack of cut-off value definition and difference among studies, which highlights the need for further exclusive evaluation to avoid future contradictory results.

# **5** Conclusion

In conclusion, miRNAs could be promising, non-invasive methods to both diagnose and predict the tumor invasion. Further studies should focus on the source of sample, grade of glioma, different populations as well as different miRNA detection methods, and cut off values, to provide clinically, fast response prognostic and diagnostic panels.

# Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

# Author contributions

FH: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review & editing. MM: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review & editing. KJ: Validation, Visualization, Writing – original draft. PA: Data curation, Validation, Visualization, Writing – original draft. SH: Data curation, Validation, Visualization, Writing – original draft. VL: Supervision, Writing – review & editing. AA: Methodology, Supervision, Writing – review & editing.

# Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

# **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2024.1357321/ full#supplementary-material

# References

1. Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, et al. NCCN guidelines insights: central nervous system cancers, version 1.2017. *J Natl Compr Cancer Netw.* (2017) 15:1331–45. doi: 10.6004/jnccn.2017.0166

2. Ludwig K, Kornblum HI. Molecular markers in glioma. J Neuro-Oncol. (2017) 134:505–12. doi: 10.1007/s11060-017-2379-y

3. Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, et al. Glioma. *Nat Rev Dis Primers*. (2015) 1:15017. doi: 10.1038/nrdp.2015.17

4. Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. *Neurooncol.* (2022) 24:v1–v95. doi: 10.1093/neuonc/ noac202

5. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA. Cancer J Clin. (2023) 73:17-48. doi: 10.3322/caac.21763

6. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *Cancer J Clin.* (2021) 71:209–49. doi: 10.3322/caac.21660

7. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. *Neuro-Oncology.* (2019) 21:v1-v100. doi: 10.1093/ neuonc/noz150

8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell.* (2004) 116:281-97. doi: 10.1016/s0092-8674(04)00045-5

9. Yoo JK, Lee JM, Kang SH, Jeon SH, Kim CM, Oh SH, et al. The novel microRNA hsa-miR-CHA1 regulates cell proliferation and apoptosis in human lung cancer by targeting XIAP. *Lung Cancer*. (2019) 132:99–106. doi: 10.1016/j.lungcan.2018.04.011

10. Lei L, Zhao X, Liu S, Cao Q, Yan B, Yang J. MicroRNA-3607 inhibits the tumorigenesis of colorectal cancer by targeting DDI2 and regulating the DNA damage repair pathway. *Apoptosis*. (2019) 24:662–72. doi: 10.1007/s10495-019-01549-5

11. Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis. (2015) 35:3–11. doi: 10.1055/s-0034-1397344

12. Ipsaro JJ, Joshua-Tor L. From guide to target: molecular insights into eukaryotic RNA-interference machinery. *Nat Struct Mol Biol.* (2015) 22:20–8. doi: 10.1038/ nsmb.2931

13. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. *Nat Rev Genet.* (2011) 12:99–110. doi: 10.1038/nrg2936

14. Xu W, San Lucas A, Wang Z, Liu Y. Identifying microRNA targets in different gene regions. *BMC Bioinform*. (2014) 15:S4. doi: 10.1186/1471-2105-15-S7-S4

15. Zhang J, Zhou W, Liu Y, Liu T, Li C, Wang L. Oncogenic role of microRNA-532-5p in human colorectal cancer via targeting of the 5'UTR of RUNX3. *Oncol Lett.* (2018) 15:7215–20. doi: 10.3892/ol.2018.8217

16. Forman JJ, Legesse-Miller A, Coller HA. A search for conserved sequences in coding regions reveals that the let-7 microRNA targets dicer within its coding sequence. *Proc Natl Acad Sci USA*. (2008) 105:14879–84. doi: 10.1073/pnas.0803230105

17. Dharap A, Pokrzywa C, Murali S, Pandi G, Vemuganti R. MicroRNA miR-324-3p induces promoter-mediated expression of RelA gene. *PLoS One.* (2013) 8:e79467. doi: 10.1371/journal.pone.0079467

18. Chen L, Yang J, Lü J, Cao S, Zhao Q, Yu Z. Identification of aberrant circulating miRNAs in Parkinson's disease plasma samples. *Brain Behav.* (2018) 8:e00941. doi: 10.1002/brb3.941

19. Lai YC, Ushio N, Rahman MM, Katanoda Y, Ogihara K, Naya Y, et al. Aberrant expression of microRNAs and the miR-1/MET pathway in canine hepatocellular carcinoma. *Vet Comp Oncol.* (2018) 16:288–96. doi: 10.1111/vco.12379

20. Ma C, Nguyen HPT, Luwor RB, Stylli SS, Gogos A, Paradiso L, et al. A comprehensive meta-analysis of circulation miRNAs in glioma as potential diagnostic biomarker. *PLoS One*. (2018) 13:e0189452. doi: 10.1371/journal.pone.0189452

21. Tang Y, Zhao S, Wang J, Li D, Ren Q, Tang Y. Plasma miR-122 as a potential diagnostic and prognostic indicator in human glioma. *Neurol Sci.* (2017) 38:1087–92. doi: 10.1007/s10072-017-2912-y

22. Huang Q, Wang C, Hou Z, Wang G, Lv J, Wang H, et al. Serum microRNA-376 family as diagnostic and prognostic markers in human gliomas. *Cancer Biomark*. (2017) 19:137–44. doi: 10.3233/CBM-160146

23. Jiang G, Mu J, Liu X, Peng X, Zhong F, Yuan W, et al. Prognostic value of miR-21 in gliomas: comprehensive study based on meta-analysis and TCGA dataset validation. *Sci Rep.* (2020) 10:4220. doi: 10.1038/s41598-020-61155-3

24. Li C, Sun J, Xiang Q, Liang Y, Zhao N, Zhang Z, et al. Prognostic role of microRNA-21 expression in gliomas: a meta-analysis. *J Neuro-Oncol.* (2016) 130:11–7. doi: 10.1007/s11060-016-2233-7

25. Zhao X, Xiao Z, Li B, Li H, Yang B, Li T, et al. miRNA-21 may serve as a promising noninvasive marker of glioma with a high diagnostic performance: a pooled analysis of 997 patients. *Ther Adv Med Oncol.* (2021) 13:1758835920987650. doi: 10.1177/1758835920987650

26. Pang C, Guan Y, Zhao K, Chen L, Bao Y, Cui R, et al. Up-regulation of microRNA-15b correlates with unfavorable prognosis and malignant progression of human glioma. *Int J Clin Exp Pathol*. (2015) 8:4943–52.

27. Sun G, Yan S, Shi L, Wan Z, Jiang N, Li M, et al. Decreased expression of miR-15b in human gliomas is associated with poor prognosis. *Cancer Biother Radiopharm.* (2015) 30:169–73. doi: 10.1089/cbr.2014.1757

28. Zhu M, Zhao W, Zhao H, Zhang J. Diagnostic and prognostic value of microRNA-193b in patients with glioma and its effect on tumor progression. *Oncol Lett.* (2019) 18:4882–90. doi: 10.3892/ol.2019.10819

29. Lan F, Yue X, Xia T. Exosomal microRNA-210 is a potentially non-invasive biomarker for the diagnosis and prognosis of glioma. *Oncol Lett.* (2020) 19:1967–74. doi: 10.3892/ol.2020.11249

30. Lai NS, Dong QS, Ding H, Miao ZL, Lin YC. MicroRNA-210 overexpression predicts poorer prognosis in glioma patients. *J Clin Neurosci*. (2014) 21:755–60. doi: 10.1016/j.jocn.2013.06.024

31. Zhang X, Cheng J, Fu L, Li Q. Overexpression of tissue microRNA10b may help predict glioma prognosis. *J Clin Neurosci.* (2016) 29:59–63. doi: 10.1016/j. jocn.2015.10.046

32. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* (2009) 6:e1000097. doi: 10.1371/journal.pmed.1000097

33. Lo CK, Mertz D, Loeb M. Newcastle-Ottawa scale: comparing reviewers to authors assessments. *BMC Med Res Methodol*. (2014) 14:45. doi: 10.1186/1471-2288-14-45

34. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. (2008)

35. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. *J Clin Epidemiol.* (2005) 58:982–90. doi: 10.1016/j. jclinepi.2005.02.022

36. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *Evid Based Ment Health*. (2019) 22:153–60. doi: 10.1136/ebmental-2019-300117

37. Doebler P, Holling H, (Eds.) Meta-analysis of diagnostic accuracy with mada, (2017)

38. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology.* (1982) 143:29–36. doi: 10.1148/ radiology.143.1.7063747

39. Obuchowski NA, Lieber ML, Wians FH Jr. ROC curves in clinical chemistry: uses, misuses, and possible solutions. *Clin Chem.* (2004) 50:1118–25. doi: 10.1373/ clinchem.2004.031823

40. Baraniskin A, Kuhnhenn J, Schlegel U, Maghnouj A, Zöllner H, Schmiegel W, et al. Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. *Neurooncol.* (2012) 14:29–33. doi: 10.1093/neuonc/nor169

41. Wang Q, Li P, Li A, Jiang W, Wang H, Wang J, et al. Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. *J Exp Clin Cancer Res.* (2012) 31:1–10. doi: 10.1186/1756-9966-31-97

42. Lai N, Wu D, Fang X, Lin Y, Chen S, Li Z, et al. Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. *Br J Cancer*. (2015) 112:1241–6. doi: 10.1038/bjc.2015.91

43. Sun J, Liao K, Wu X, Huang J, Zhang S, Lu X. Serum microRNA-128 as a biomarker for diagnosis of glioma. *Int J Clin Exp Med.* (2015) 8:456.

44. Chai C, Song L-J, Yang B, Han S-Y, Li X-Q, Li M. Circulating miR-199a-3p in plasma and its potential diagnostic and prognostic value in glioma. *Eur Rev Med Pharmacol Sci.* (2016) 20:4885.

45. Xiao Y, Zhang L, Song Z, Guo C, Zhu J, Li Z, et al. Potential diagnostic and prognostic value of plasma circulating microRNA-182 in human glioma. *Med Sci Monit.* (2016) 22:855. doi: 10.12659/msm.897164

46. Yue X, Lan F, Hu M, Pan Q, Wang Q, Wang J. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma. *J Neurosurg.* (2016) 124:122–8. doi: 10.3171/2015.1.JNS141577

47. Zhao S, Yue S, Yang Q, Cai W, Jin C, Gao G, et al. Serum microRNA-451a expression and its diagnostic value in glioma. *Int J Clin Exp Pathol.* (2016) 9:3678–82.

48. Xu W, Liang W, Dai Y. A three-miRNA signature as a potential biomarker for the diagnosis of glioma. *Int J Clin Exp Pathol.* (2017) 10:2814–23.

49. Lan F, Qing Q, Pan Q, Hu M, Yu H, Yue X. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma. *Cell Oncol.* (2018) 41:25–33. doi: 10.1007/s13402-017-0355-3

50. Santangelo A, Imbrucè P, Gardenghi B, Belli L, Agushi R, Tamanini A, et al. A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker. *J Neuro-Oncol.* (2018) 136:51–62. doi: 10.1007/s11060-017-2639-x

51. Kopkova A, Sana J, Machackova T, Vecera M, Radova L, Trachtova K, et al. Cerebrospinal fluid microRNA signatures as diagnostic biomarkers in brain tumors. *Cancers*. (2019) 11:1546. doi: 10.3390/cancers11101546

52. Ohno M, Matsuzaki J, Kawauchi J, Aoki Y, Miura J, Takizawa S, et al. Assessment of the diagnostic utility of serum microRNA classification in patients with diffuse glioma. *JAMA Netw Open*. (2019) 2:e1916953.

53. Wang J, Che F, Zhang J, Zhang M, Xiao S, Liu Y, et al. Diagnostic and prognostic potential of serum cell-free microrna-214 in glioma. *World Neurosurg.* (2019) 125:e1217-25. doi: 10.1016/j.wneu.2019.02.009

54. Zhang Y, Ta W-W, Sun P-F, Meng Y-F, Zhao C-Z. Diagnostic and prognostic significance of serum miR-145-5p expression in glioblastoma. *Int J Clin Exp Pathol.* (2019) 12:2536.

55. Chen P, Zhang G, Zhou Q, Li Z. Plasma microRNA-720 may predict prognosis and diagnosis in glioma patients. *Biosci Rep.* (2020) 40:BSR20201449. doi: 10.1042/BSR20201449

56. Sun J, Sun Z, Gareev I, Yan T, Chen X, Ahmad A, et al. Exosomal miR-2276-5p in plasma is a potential diagnostic and prognostic biomarker in glioma. *Front Cell Dev Biol.* (2021) 9:671202. doi: 10.3389/fcell.2021.671202

57. Catelan S, Olioso D, Santangelo A, Scapoli C, Tamanini A, Pinna G, et al. miRNAs in serum exosomes for differential diagnosis of brain metastases. *Cancers.* (2022) 14:3493. doi: 10.3390/cancers14143493

58. Geng L, Xu J, Zhu Y, Hu X, Liu Y, Yang K, et al. Targeting miR-9 in glioma stem cell-derived extracellular vesicles: a novel diagnostic and therapeutic biomarker. *Transl Oncol.* (2022) 22:101451. doi: 10.1016/j.tranon.2022.101451

59. Nikolova E, Georgiev C, Laleva L, Milev M, Spiriev T, Stoyanov S, et al. Diagnostic, grading and prognostic role of a restricted miRNAs signature in primary and metastatic brain tumours. Discussion on their therapeutic perspectives. *Mol Gen Genet.* (2022) 297:357–71. doi: 10.1007/s00438-021-01851-5

60. Wu J, al-Zahrani A, Beylerli O, Sufianov R, Talybov R, Meshcheryakova S, et al. Circulating miRNAs as diagnostic and prognostic biomarkers in high-grade gliomas. *Front Oncol.* (2022) 12:898537. doi: 10.3389/fonc.2022.898537

61. Qu S, Guan J, Liu Y. Identification of microRNAs as novel biomarkers for glioma detection: a meta-analysis based on 11 articles. *J Neurol Sci.* (2015) 348:181–7. doi: 10.1016/j.jns.2014.11.036

62. He J, Jiang Y, Liu L, Zuo Z, Zeng C. Circulating microRNAs as promising diagnostic biomarkers for patients with glioma: a Meta-analysis. *Front Neurol.* (2021) 11:610163. doi: 10.3389/fneur.2020.610163

63. Aloizou AM, Pateraki G, Siokas V, Mentis AA, Liampas I, Lazopoulos G, et al. The role of MiRNA-21 in gliomas: Hope for a novel therapeutic intervention? *Toxicol Rep.* (2020) 7:1514–30. doi: 10.1016/j.toxrep.2020.11.001

64. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. *Mol Cell Biol.* (2008) 28:5369–80. doi: 10.1128/MCB.00479-08

65. Han L, Yue X, Zhou X, Lan FM, You G, Zhang W, et al. MicroRNA-21 expression is regulated by  $\beta$ -catenin/STAT3 pathway and promotes glioma cell invasion by direct targeting RECK. *CNS Neurosci Ther.* (2012) 18:573–83. doi: 10.1111/j.1755-5949.2012.00344.x

66. Yang M, Bai HX, Yang L. MicroRNA-21 expression in the prognosis of low-grade gliomas: data from the cancer genome atlas (TCGA) project. *J Neuro-Oncol.* (2017) 134:241–2. doi: 10.1007/s11060-017-2500-2

67. Barbano R, Palumbo O, Pasculli B, Galasso M, Volinia S, D'Angelo V, et al. A miRNA signature for defining aggressive phenotype and prognosis in gliomas. *PLoS One.* (2014) 9:e108950. doi: 10.1371/journal.pone.0108950

68. Shang C, Hong Y, Guo Y, Liu YH, Xue YX. miR-128 regulates the apoptosis and proliferation of glioma cells by targeting RhoE. *Oncol Lett.* (2016) 11:904–8. doi: 10.3892/ol.2015.3927

69. Cai J, Fang L, Huang Y, Li R, Xu X, Hu Z, et al. Simultaneous overactivation of Wnt/ $\beta$ -catenin and TGF $\beta$  signalling by miR-128-3p confers chemoresistance-associated metastasis in NSCLC. *Nat Commun.* (2017) 8:15870. doi: 10.1038/ncomms15870

70. Cicchillitti L, di Stefano V, Isaia E, Crimaldi L, Fasanaro P, Ambrosino V, et al. Hypoxia-inducible factor  $1-\alpha$  induces miR-210 in normoxic differentiating myoblasts. *J Biol Chem.* (2012) 287:44761–71. doi: 10.1074/jbc.M112.421255

71. Toraih EA, El-Wazir A, Abdallah HY, Tantawy MA, Fawzy MS. Deregulated microRNA signature following glioblastoma irradiation. *Cancer Control.* (2019) 26:1073274819847226. doi: 10.1177/1073274819847226

72. Shang C, Hong Y, Guo Y, Liu Y-h, Xue Y-x. MiR-210 up-regulation inhibits proliferation and induces apoptosis in glioma cells by targeting SIN3A. *Med Sci Monit.* (2014) 20:2571. doi: 10.12659/MSM.892994

73. Li M, Li J, Liu L, Li W, Yang Y, Yuan J. MicroRNA in human glioma. *Cancers*. (2013) 5:1306–31. doi: 10.3390/cancers5041306

74. Conti A, Aguennouz MH, la Torre D, Tomasello C, Cardali S, Angileri FF, et al. miR-21 and 221 upregulation and miR-181b downregulation in human grade II–IV astrocytic tumors. *J Neuro-Oncol.* (2009) 93:325–32. doi: 10.1007/s11060-009-9797-4

75. Yang L, Ma Y, Xin Y, Han R, Li R, Hao X. Role of the microRNA 181 family in glioma development. *Mol Med Rep.* (2018) 17:322–9. doi: 10.3892/mmr.2017.7895

76. Zehavi L, Avraham R, Barzilai A, Bar-Ilan D, Navon R, Sidi Y, et al. Silencing of a large microRNA cluster on human chromosome 14q32 in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor 1 receptor. *Mol Cancer*. (2012) 11:44. doi: 10.1186/1476-4598-11-44

77. Shao N, Wang L, Xue L, Wang R, Lan Q. Plasma miR-454-3p as a potential prognostic indicator in human glioma. *Neurol Sci.* (2015) 36:309–13. doi: 10.1007/s10072-014-1938-7

78. Zhi F, Shao N, Wang R, Deng D, Xue L, Wang Q, et al. Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma. *Neurooncol.* (2015) 17:383–91. doi: 10.1093/neuonc/nou169

79. Laghari AA, Suchal ZA, Avani R, Khan DA, Kabani AS, Nouman M, et al. Prognostic potential of microRNAs in glioma patients: a meta-analysis. *ASJO*. (2022) 8:92–103. doi: 10.1055/s-0042-1744448

80. Zhang Y, Chen J, Xue Q, Wang J, Zhao L, Han K, et al. Prognostic significance of microRNAs in glioma: a systematic review and meta-analysis. *Biomed Res Int.* (2019) 2019:1–14. doi: 10.1155/2019/4015969

81. Jenike AE, Halushka MK. miR-21: a non-specific biomarker of all maladies. Biomark Res. (2021) 9:18. doi: 10.1186/s40364-021-00272-1

82. Wu L, Li G, Feng D, Qin H, Gong L, Zhang J, et al. MicroRNA-21 expression is associated with overall survival in patients with glioma. *Diagn Pathol.* (2013) 8:200. doi: 10.1186/1746-1596-8-200

83. Song Y, Zhang J, He M, Xu J. Prognostic role of microRNA 222 in patients with glioma: a meta-analysis. *Biomed Res Int.* (2020) 2020:4689689. doi: 10.1155/2020/4689689

84. Zhou Y, Wang X, Liu Z, Huang X, Li X, Cheng K, et al. Prognostic role of microRNA-155 expression in gliomas: a meta-analysis. *Clin Neurol Neurosurg.* (2019) 176:103–9. doi: 10.1016/j.clineuro.2018.12.005

85. Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stühler K, Meyer HE, et al. Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. *Brain Pathol.* (2010) 20:539–50. doi: 10.1111/j.1750-3639.2009.00328.x